Emergency Use Authorization of Hetero's Tocira gets approval from DCGI for Covid treatment in adults

Image credit:- CDSCO

On Monday, 6 September 2021, Drug Controller General of India (DCGI) has approved Emergency Use Authorization (EUA) for Hetero's generic version of Tocilizumab in India for the treatment of COVID-19 in hospitalised adults.

• According to the company statement, this authorisation will enable the medical practitioners to use the generic drug Tocilizumab for the treatment of COVID-19 in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

"We are pleased with the approval of Hetero's Tocilizumab (Tocira) in India. This demonstrates our technical capabilities and commitment to bringing important therapeutics relevant to COVID care. This approval is extremely crucial for supply security in India considering a global shortage of Tocilizumab. We will be working closely with the Government to ensure equitable distribution," said Dr B. Partha Saradhi Reddy, Chairman of Hetero Group.

Hetero's TOCIRA (Tocilizumab) will be marketed by its associate company 'Hetero Healthcare' in India with the support of its strong distribution network across the country.

• The drug will be manufactured by Hetero's biologics arm 'Hetero Biopharma' at its dedicated biologics facility, based at Jadcherla in Hyderabad.

Hetero's Tocilizumab 400mg/20ml is the biosimilar version of Roche's Actemra/RoActemra ® and will be available from September end.